Moreover, although shRNA-mediated loss of LATS1 did not affect primary tumor growth of HCC cells in xenotransplanted immunodeficient mice, it significantly reduced tumor growth under Srf treatment (Fig. 1c and Supplementary Fig. 1f). This evidence concerns the gene LATS1 and hepatocellular carcinoma.